Bioplus Acquisition Corp Stock EBITDA
BioPlus Acquisition Corp fundamentals help investors to digest information that contributes to BioPlus Acquisition's financial success or failures. It also enables traders to predict the movement of BioPlus Stock. The fundamental analysis module provides a way to measure BioPlus Acquisition's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioPlus Acquisition stock.
BioPlus |
BioPlus Acquisition Corp Company EBITDA Analysis
BioPlus Acquisition's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current BioPlus Acquisition EBITDA | (1.17 M) |
Most of BioPlus Acquisition's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioPlus Acquisition Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, BioPlus Acquisition Corp reported earnings before interest,tax, depreciation and amortization of (1.17 Million). This is 100.0% lower than that of the Capital Markets sector and significantly lower than that of the Financials industry. The ebitda for all United States stocks is 100.03% higher than that of the company.
BioPlus EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioPlus Acquisition's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioPlus Acquisition could also be used in its relative valuation, which is a method of valuing BioPlus Acquisition by comparing valuation metrics of similar companies.BioPlus Acquisition is currently under evaluation in ebitda category among its peers.
BioPlus Fundamentals
| Return On Asset | -0.0072 | |||
| Current Valuation | 215.16 M | |||
| Shares Outstanding | 19.37 M | |||
| Shares Owned By Insiders | 48.69 % | |||
| Shares Owned By Institutions | 51.31 % | |||
| Number Of Shares Shorted | 1.64 K | |||
| Price To Earning | (3.62) X | |||
| EBITDA | (1.17 M) | |||
| Net Income | 2 M | |||
| Cash And Equivalents | 294.69 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 5 M | |||
| Debt To Equity | 7.23 % | |||
| Current Ratio | 2.96 X | |||
| Book Value Per Share | (0.86) X | |||
| Cash Flow From Operations | (691.47 K) | |||
| Short Ratio | 0.03 X | |||
| Earnings Per Share | 0.21 X | |||
| Price To Earnings To Growth | (7.93) X | |||
| Target Price | 20.0 | |||
| Number Of Employees | 38 | |||
| Beta | 0.14 | |||
| Market Capitalization | 208.98 M | |||
| Total Asset | 238.32 M | |||
| Retained Earnings | (14.78 M) | |||
| Working Capital | 21.89 K | |||
| Current Asset | 183.69 M | |||
| Current Liabilities | 152.76 M | |||
| Z Score | 24.97 | |||
| Net Asset | 238.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in BioPlus Stock
If you are still planning to invest in BioPlus Acquisition Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPlus Acquisition's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |